Management of Hyperprolactinemia and Chronic Widespread Pain

Diagnostic Approach

The American College of Physicians recommends a systematic workup to determine the cause of hyperprolactinemia, starting with repeat prolactin measurement, medication review, and measurement of luteinizing hormone levels 1
Repeat the prolactin measurement in the morning while fasting to exclude stress-induced or pulsatile elevation, as a single elevated value may be spurious 1, 2
Consider serial measurements 20-60 minutes apart using an indwelling cannula if the elevation remains modest on repeat testing 1
Review all medications immediately, particularly antipsychotics, antidepressants, antihypertensive agents, and drugs that increase bowel motility, as these are the most common causes of hyperprolactinemia 1, 2
Screen for pregnancy, primary hypothyroidism, liver disease, and chronic kidney disease 1, 2
Assess for macroprolactinemia by requesting the laboratory perform polyethylene glycol precipitation, especially since the patient is relatively asymptomatic regarding typical hyperprolactinemia symptoms 1, 2
Macroprolactinemia is present in 10-40% of patients with hyperprolactinemia and does not require treatment 1, 2

Measure serum luteinizing hormone (LH) levels in all patients with confirmed hyperprolactinemia to establish the etiology and determine if this is central (hypothalamic-pituitary) versus peripheral 3, 1
If LH is low or low-normal, repeat prolactin measurement to ensure persistent elevation before proceeding to imaging 3, 1

Obtain pituitary MRI only if prolactin remains significantly elevated on repeat testing (generally >100 µg/L suggests prolactinoma) or if LH is low/low-normal with persistent hyperprolactinemia 1
For modest elevations like this patient's level, imaging may not be immediately necessary if secondary causes are identified 1

Address the chronic widespread pain with a holistic, multimodal approach including patient education on pain neurophysiology, physical therapy, occupational therapy, and behavioral therapy 4, 5
Use brief pain assessment tools like the 3-item PEG (Pain intensity, Enjoyment of life, General activity) to track pain over time in clinical practice 4
Focus treatment goals on restoring function, decreasing pain severity, and improving quality of life rather than complete pain elimination 4, 5
Consider interdisciplinary team involvement, particularly if there are co-occurring psychiatric disorders or substance use concerns 4

Initiate cabergoline as first-line therapy at doses up to 2 mg/week for smaller prolactinomas, as it has superior effectiveness (83% normalization rate) and better tolerability compared to bromocriptine 1, 6
Monitor prolactin levels 1-3 months after initiating treatment and every 3-6 months until stabilized 2
For patients requiring >2 mg/week, perform baseline echocardiogram and annual echocardiographic surveillance due to cardiac valvulopathy risk 6
Start with small nocturnal dose increments to reduce gastrointestinal intolerance and postural hypotension 6

Refer to endocrinology if prolactin remains persistently elevated after excluding common causes 3, 1
Refer to endocrinology if patient develops symptoms of pituitary mass effect (headaches, visual field defects) 1
Refer to endocrinology if resistance to dopamine agonist therapy occurs (failure to normalize prolactin after 3-6 months of maximally tolerated doses) 6